Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial.
暂无分享,去创建一个
T. Hiro | Y. Morino | K. Tsujita | K. Kozuma | K. Miyauchi | H. Otake | T. Shinke | K. Hibi | K. Uno | J. Ako | Michael J. Louie | Yoshiharu Takagi | M. J. Louie
[1] Daniel E Forman,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.
[2] J Wouter Jukema,et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018, The New England journal of medicine.
[3] T. Hiro,et al. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design. , 2018, Journal of cardiology.
[4] Deepak L. Bhatt,et al. 2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. , 2017, Circulation. Cardiovascular quality and outcomes.
[5] Jennifer G. Robinson,et al. Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. , 2016, The American journal of cardiology.
[6] W. Koenig,et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. , 2016, JAMA.
[7] A. Guerrero,et al. 2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines - Executive Summary , 2016, ASEAN heart journal : Official journal of the ASEAN Federation of Cardiology.
[8] P. Serruys,et al. Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. , 2016, American heart journal.
[9] K. Sakamoto,et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. , 2015, Journal of the American College of Cardiology.
[10] T. Jernberg,et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. , 2015, European heart journal.
[11] A. Jaffe,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[12] T. Kurata,et al. Effect of combination of ezetimibe and a statin on coronary plaque regression in patients with acute coronary syndrome , 2014 .
[13] S. Kihara,et al. Other types of primary hyperlipoproteinemia(hyperlipidemia). Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version. , 2013, Journal of atherosclerosis and thrombosis.
[14] Peter Libby,et al. Effect of two intensive statin regimens on progression of coronary disease. , 2011, The New England journal of medicine.
[15] R. Califf,et al. 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.
[16] Stephen J. Nicholls,et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. , 2010, Journal of the American College of Cardiology.
[17] Carl J Pepine,et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. , 2006, The New England journal of medicine.
[18] Paul Schoenhagen,et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.
[19] C. Tracy,et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. , 2001, Journal of the American College of Cardiology.
[20] J. Jost,et al. Executive Summary , 1998, OECD Reviews of Pension Systems: Peru.
[21] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[22] S. Kihara,et al. Coronary artery disease. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version. , 2014, Journal of atherosclerosis and thrombosis.
[23] M. Taskinen,et al. ESC/EAS Guidelines for the Management of Dyslipidaemias , 2013 .
[24] ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations. , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.